Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 67

Results For "generic"

706 News Found

Zydus and TLC sign agreement to market Liposomal Amphotericin B in India
News | May 26, 2021

Zydus and TLC sign agreement to market Liposomal Amphotericin B in India

With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage


Orchid Pharma to transfer IKKT undertaking to JV with Bionpharma
News | May 25, 2021

Orchid Pharma to transfer IKKT undertaking to JV with Bionpharma

The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr


Glenmark receives ANDA approval for Icatibant Injection
News | May 25, 2021

Glenmark receives ANDA approval for Icatibant Injection

This marks Glenmark's first synthetic decapeptide injectable approval


Outlook intact for Dr. Reddy's Laboratories : ICICI Securities
News | May 18, 2021

Outlook intact for Dr. Reddy's Laboratories : ICICI Securities

India sales grew 23.5% YoY with consolidation of Wockhardt products


Alembic gets USFDA approval for Lurasidone Hydrochloride tablets
News | May 15, 2021

Alembic gets USFDA approval for Lurasidone Hydrochloride tablets

Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder


Dr. Reddy's Sputnik V India price is Rs. 995.40
News | May 15, 2021

Dr. Reddy's Sputnik V India price is Rs. 995.40

The company is working closely with its six manufacturing partners in India


Dr. Reddy's launches Ertapenem in US
News | May 12, 2021

Dr. Reddy's launches Ertapenem in US

The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health


CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
News | May 11, 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.


DCGI approves anti-COVID drug developed by DRDO
Policy | May 10, 2021

DCGI approves anti-COVID drug developed by DRDO

The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production


Alembic announces USFDA approval for two drugs
News | May 06, 2021

Alembic announces USFDA approval for two drugs

Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA